Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01281917 · ClinicalTrials.gov registry record · Phase 2
Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma
A Phase 2 study of Non-Hodgkin's Lymphoma, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 18
- Study locations
NCT01281917: Completed Phase 2 study of Non-Hodgkin's Lymphoma, sponsored by University of Wisconsin, Madison.
NCT01281917 is a Phase 2 study of Non-Hodgkin's Lymphoma that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 40 participants, below the 221-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (82% lower). The trial reports 18 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01281917, a Phase 2 study of Non-Hodgkin's Lymphoma, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 18
- Study locations
Study Summary
The investigators want to find out if the drugs Velcade and temsirolimus given together are effective in treating cancer. Velcade and temsirolimus are each FDA approved individually for certain types of cancer (Velcade for multiple myeloma and mantle cell lymphoma, and temsirolimus for renal cell carcinoma) but are not currently approved in combination for B-cell non-Hodgkin lymphoma. The investigators are trying to find out if giving these 2 drugs together will improve the period of time that the patient's cancer is stopped or slowed from growing and causing symptoms.
Primary Outcome
The primary objective of this study is to determine whether Velcade in combination with temsirolimus provides benefit to subjects with relapsed or refractory B-cell non-Hodgkin lymphoma as assessed by overall response rate (ORR) to therapy. ORR is the sum of patients with a Complete Response and Partial Response to therapy. Per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete REsponse (CR), Disappearance of all target lesions; P
Conditions Studied
Interventions
- DRUG Temsirolimus
- DRUG Velcade
Study Locations (18)
Wisconsin
- Aurora Baycare Medical Center-GreenBay - Green Bay
- St Vincent Regional Cancer Center CCOP - Green Bay
- Bellin Memorial Hospital, Inc - Green Bay
- Gunderson Lutheran Health System - La Crosse
- UW Health Oncology- 1 S Park - Madison
- University Of Wisconsin Cancer Center - Madison
- Aurora BayCare Medical Center - Marinette
- Marshfield Clinic - Marshfield
- Columbia St Mary's, Inc - Milwaukee
- Medical College of Wisconsin - Milwaukee
- Aurora Sheboygan Memorial Medical Center - Sheboygan
- Aurora Medical Center in Summit - Summit
- Aurora Medical Center in Two Rivers - Two Rivers
- Waukesha Memorial Hospital - Waukesha
- Aspirus Wausau Hospital - Wausau
- Aurora Health Care Metro, Inc. - Wauwatosa
- UW Cancer Center-Riverview - Wisconsin Rapids
South Dakota
- Rapid City Regional Hospital John T. Vucurevich Cancer Care Institute - Rapid City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2011-02 |
| Est. Completion | 2014-06 |
| Phase | Phase 2 |
What the finished NCT01281917 record still lists
NCT01281917 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 221-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Non-Hodgkin's Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Temsirolimus is the first listed.
NCT01281917 lists 18 locations in 2 states (Wisconsin, South Dakota).
Frequently Asked Questions
What is clinical trial NCT01281917 about?
NCT01281917 is a clinical study titled "Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma". The investigators want to find out if the drugs Velcade and temsirolimus given together are effective in treating cancer. Velcade and temsirolimus are each FDA approved individually for certain types of cancer (Velcade for multiple myeloma and mantle cell lymphoma, and temsirolimus for renal cell ca...
What is the current status of trial NCT01281917?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2011-02. Estimated completion is 2014-06.
What conditions does trial NCT01281917 study?
This clinical trial studies the following conditions: Non-Hodgkin's Lymphoma.
What interventions are being tested in trial NCT01281917?
The interventions under investigation include: Temsirolimus (DRUG), Velcade (DRUG).
Who is sponsoring clinical trial NCT01281917?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01281917 being conducted?
This trial has 18 study locations across South Dakota, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin's Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01281917's enrollment target sits among peer trials
40 35th of 63 higher than 29 of 63 other Non-Hodgkin's Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Hodgkin's Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cord Blood Transplant in Adults With Blood Cancers
RECRUITING · Phase 2
-
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
RECRUITING · Phase 2
-
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
RECRUITING · Phase 2
-
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
RECRUITING · Phase 2
-
Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas
ACTIVE NOT RECRUITING · Phase 2
-
Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia